Aeglea Biotherapeutics
United States
About Aeglea Biotherapeutics
103 articles with Aeglea Biotherapeutics
-
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 17, 2023
3/17/2023
Aeglea BioTherapeutics, Inc. announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company's 2016 Equity Incentive Plan, but under the terms of the company's 2018 Equity Inducement Plan.
-
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates
3/2/2023
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.
-
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
1/6/2023
Aeglea BioTherapeutics today announced an update to its corporate structure.
-
Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022
12/2/2022
Aeglea BioTherapeutics, Inc. announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea's common stock to Jeffrey M. Goldberg as a material inducement to his appointment as the chief executive officer of Aeglea in accordance with Rule 5635 of the Nasdaq Listing Rules.
-
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
11/30/2022
Aeglea BioTherapeutics, Inc. today announced the appointment of Jeffrey M. Goldberg as president, chief executive officer and member of the board of directors effective November 29, 2022.
-
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
11/15/2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.
-
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
11/3/2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates.
-
Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment
10/19/2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) today announced that it will host a key opinion leader (KOL) webinar on Classical Homocystinuria, and Aeglea's potential treatment and lead clinical asset pegtarviliase on Thursday, October 27, 2022 at 10:00 AM Eastern Time.
-
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program
10/4/2022
Aeglea BioTherapeutics, Inc. today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystin is underway.
-
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
8/29/2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2.
-
Anthony Quinn has stepped down from his role as chief executive officer and transitioned to an advisory role. Jim Kastenmayer, general counsel, will assume the post on an interim basis.
-
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
8/24/2022
Aeglea BioTherapeutics, Inc. today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria.
-
Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency
8/18/2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), today announced that a Marketing Authorization Application (MAA) for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D) has been submitted to and successfully validated by the European Medicines Agency (EMA).
-
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
8/4/2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2022 and provided program updates.
-
The FDA requested more data on effectiveness, particularly evidence that shows plasma arginine and metabolic reduction can predict clinical benefit in patients living with ARG1-D.
-
Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
6/2/2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding the company's Biologics License Application (BLA) for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).
-
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
5/5/2022
Aeglea BioTherapeutics, Inc. announced financial results for the first quarter 2022 and provided program updates.
-
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market
5/5/2022
Aeglea BioTherapeutics, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities of the Company in a registered direct offering for gross proceeds to Aeglea of approximately $45 million, prior to deducting placement agent fees and estimated offering expenses.
-
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
4/12/2022
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for pegzilarginase for the treatment of Arginase 1 Deficiency.
-
As Aeglea presents the data this week at the Society for Inherited Metabolic Disorders (SIMD), its stock has responded to both announcements with a strong leap.